Sylwia Ammoun
Plymouth, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Correction: Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
Journal: Oncogene
Published: September 26, 2024
Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
Journal: Oncogene
Published: April 05, 2024
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.
Journal: International journal of molecular sciences
Published: December 12, 2020
Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
Journal: Cancer research
Published: November 20, 2020
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: September 27, 2018
Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.
Journal: Oncogene
Published: November 16, 2016
An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Journal: Cancer research
Published: October 17, 2016
The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Journal: Oncogene
Published: March 30, 2015
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Journal: Molecular oncology
Published: May 20, 2014
Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas.
Journal: Histopathology
Published: September 06, 2012
Last Updated: 09/26/2026